Cell News and Research

RSS

Dutch researcher sheds new light on coronaviruses

Using novel techniques, Dutch researcher Matthijs Raaben has cast new light on the replication of coronaviruses, a family of viruses including the cause of SARS. He has shown, using luminescent viruses, how coronaviruses use host cells and how we can use the intracellular processes to attack the virus.

21 Oct 2009

Controlled formation of patchy particles may serve as drug-delivery vehicles to combat disease

Physicists, chemists and engineers at the University of Pennsylvania have demonstrated a novel method for the controlled formation of patchy particles, using charged, self-assembling molecules that may one day serve as drug-delivery vehicles to combat disease and perhaps be used in small batteries that store and release charge.

21 Oct 2009

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

An exon skipping PPMO has demonstrated dramatic effects in the prevention and treatment of severely affected, dystrophin and utrophin-deficient mice, preventing severe deterioration of the treated animals and extending their lifespan.

21 Oct 2009

Amputation prevention tips for diabetic patients

While "One Foot, Two Foot, Red Foot, Blue Foot" may be the opening line of a humorous children's book by Dr. Seuss, foot complications are no laughing matter to the 20 million Americans with diabetes. According to the American Orthopaedic Foot & Ankle Society (AOFAS), ulceration, infection, and gangrene are the most common foot and ankle problems of the diabetic patient.

21 Oct 2009

Researchers show how to make stem cell therapies safer for spinal injury patients

Animal research is suggesting new ways to aid recovery after spinal cord injury. New studies demonstrate that diet affects recovery rate and show how to make stem cell therapies safer for spinal injury patients. The findings were presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

21 Oct 2009

Suntron's Phoenix, Arizona facility receives ISO 13485:2003 certification

Suntron Corporation, a leader in the area of integrated Electronics Manufacturing Solutions (EMS) and Commercial Off The Shelf (COTS) technology with six (6) North American production facilities, announced today they have received their International Organization for Standardization (ISO) 13485:2003 certification for their Southwest Operations in Phoenix, AZ.

21 Oct 2009

Genomes of two E. coli bacteria strains sequenced and analyzed

An international team of researchers from the United States, Korea, and France has sequenced and analyzed the genomes of two important laboratory strains of E. coli bacteria, one used to study evolution and the other to produce proteins for basic research or practical applications. The findings will help guide future research and will also open a window to a deeper understanding of classical research that is the foundation of our understanding of basic molecular biology and genetics.

21 Oct 2009

New workflow automation system from Illumina

At the 59th annual meeting of the American Society of Human Genetics, Illumina, Inc. announced the launch and immediate availability of cBot, a new standard for ease-of-use and sequencing workflow automation.

From Illumina, Inc. 21 Oct 2009

Bill & Melinda Gates Foundation's initiative to transform health in developing countries

The Bill & Melinda Gates Foundation today announced 76 grants of US$100,000 each to pursue bold ideas for transforming health in developing countries. The grants support researchers across 16 countries, including nine in Europe and Africa with ideas as diverse as using the power of sunlight to kill malaria-causing mosquito larvae and developing a device that repels mosquitoes without insecticides.

21 Oct 2009

Retinal prosthesis restores partial vision to people who are totally blind

Two experimental treatments, a retinal prosthesis and fetal tissue transplant, restored some vision to people with blinding eye diseases. The findings, presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health, may lead to new treatments for the blind. Researchers also reported that an engineered protein restored vision in an animal model and identified ways to improve stem cell treatments.

21 Oct 2009

GlycoMimetics raises $38 million through venture financing

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the company has raised $38 million in its latest round of venture financing. New investor Genzyme Ventures joined returning investors New Enterprise Associates, The Novartis Venture Fund, Anthem Capital and Alliance Technology Ventures in the round.

21 Oct 2009

Rice University scientists win NIH stimulus funds to study influenza A

Rice University scientists have won a $1.5 million grant from the National Institutes of Health to scrutinize the influenza A virus for clues that could lead to more effective antiviral drugs. Strains of influenza A include this year's pandemic H1N1 variety, some seasonal varieties and the much-feared H5N1 bird flu.

21 Oct 2009

Simcere and OSI Pharmaceuticals to market KDR/Kit inhibitor OSI-930 in China

Simcere Pharmaceutical Group ("Simcere" or the "Company"), a leading pharmaceutical company specializing in development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced an agreement with OSI Pharmaceuticals, Inc., to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.

21 Oct 2009

Inovio Biomedical highlights its advances in SynCon DNA vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced that Dr. David B. Weiner, Chairman of Inovio’s Scientific Advisory Board, highlighted advances in electroporation-delivered SynCon™ DNA vaccines compared to other leading vaccine technologies at the AIDS Vaccine 2009 Conference being held this week in Paris, France.

21 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

StemCells, Inc. announced today new preclinical data showing that its human neural stem cells protect cone photoreceptors (cones) in the eye from progressive degeneration and preserve visual function long term.

20 Oct 2009

Researchers use biotechnological tools to find a cure for Alzheimer's disease

No one has yet found a cure or a way to prevent people from developing Alzheimer's disease. Researchers from the Swedish University of Agricultural Sciences, among others, are breaking new ground in biotechnology to find new tools that can help provide new solutions.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

TechnoVax receives NIH grant to further the development of its VLP-based, vaccine program

TechnoVax, Inc., a biotechnology developer of novel vaccines was awarded a three-year $2.9 million SBIR phase II grant from the National Institutes of Health to further the development of its VLP-based, vaccine program.

20 Oct 2009